Irinotecan plus S-1 for liver metastases of gastric cancer.

Kochi, Mitsugu; Fujii, Masashi; Kanamori, Noriaki; Kaiga, Teruo; Okubo, Riki; Hagiwara, Ken; Funada, Tomoya; Tamegai, Hidenori; Takayama, Tadatoshi

Kochi, Mitsugu; Fujii, Masashi; Kanamori, Noriaki; Kaiga, Teruo; Okubo, Riki; Hagiwara, Ken; Funada, Tomoya; Tamegai, Hidenori; Takayama, Tadatoshi.

Affiliation

Kochi M; Department of Digestive Surgery, Nihon University School of Medicine, 30-1 Ohyaguchi Kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. gann@med.nihon-u.ac.jp

Hepatogastroenterology ; 56(96): 1755-9, 2009.

Article in En | MEDLINE | ID: mdl-20214232

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Liver Neoplasms/drug therapy; Stomach Neoplasms/pathology; Adult; Aged; Camptothecin/administration & dosage; Camptothecin/adverse effects; Camptothecin/analogs & derivatives; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms/mortality; Liver Neoplasms/secondary; Male; Middle Aged; Oxonic Acid/administration & dosage; Oxonic Acid/adverse effects; Stomach Neoplasms/mortality; Tegafur/administration & dosage; Tegafur/adverse effects

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Stomach Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Liver Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Hepatogastroenterology Year: 2009 Type: Article Affiliation country: Japan

Search on Google

Add to My VHL

XML

PubMed Links